Insider · CIK 0001890736
Mai-Britt Zocca
Files at IOBT (IO Biotech, Inc.). First filing Dec 23, 2024, latest Dec 23, 2024.
Mai-Britt Zocca files SEC Form 4 as CEO and director at IOBT (IO Biotech, Inc.). Since Dec 23, 2024, Mai-Britt Zocca has reported 1 open-market buy worth $10k and 0 open-market sells worth $0, the latest filed on Dec 23, 2024.
A track record needs three past buys with six months of prices behind them; Mai-Britt Zocca has 0, so none is measured yet.
The newest scored trade: bought $10k of IOBT on Dec 23, 2024, filed Dec 23, 2024, scored 46 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | IO Biotech, Inc. | $10k 12,500 shares | +33% | - |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +580,000 | $0.00 | $0 | 580,000 | Apr 4, 2025 |
| Dec 23, 2024 | IOBT IO Biotech, Inc. | POpen-market purchase Common Stock | +12,500 | $0.81 | $10k | 49,891 | Dec 23, 2024 |
Questions about Mai-Britt Zocca
Answered from the filings on this page, as of the latest one.
Is Mai-Britt Zocca buying or selling?
Not in the last 12 months. Mai-Britt Zocca's latest open-market trade on SEC Form 4 was bought $10k of IOBT on Dec 23, 2024.
How did Mai-Britt Zocca's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mai-Britt Zocca has 0.
Where does Mai-Britt Zocca file Form 4?
Mai-Britt Zocca has filed Form 4 at IOBT (IO Biotech, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.